119 related articles for article (PubMed ID: 12530060)
41. ICBP90 mediates Notch signaling to facilitate human hepatocellular carcinoma growth.
Fu H; Xing F; Lv Y; Zeng B; You P; Liu J
Tissue Cell; 2018 Oct; 54():65-71. PubMed ID: 30309512
[TBL] [Abstract][Full Text] [Related]
42. p53 modulation of DNA topoisomerase IIalpha gene expression.
Joshi AA; Wang Q; Suttle DP
Cell Biochem Biophys; 2000; 33(2):209-16. PubMed ID: 11325041
[No Abstract] [Full Text] [Related]
43. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
44. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
Lok CN; Lang AJ; Mirski SE; Cole SP
Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
[TBL] [Abstract][Full Text] [Related]
45. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
46. A concern regarding the current confusion with the human homolog of mouse Np95, ICBP90/UHRF1.
Unoki M; Bronner C; Mousli M
Radiat Res; 2008 Feb; 169(2):240-4. PubMed ID: 18220474
[TBL] [Abstract][Full Text] [Related]
47. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
Zha S; Isaacs WB
Mol Cancer Res; 2005 Feb; 3(2):110-8. PubMed ID: 15755877
[TBL] [Abstract][Full Text] [Related]
48. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells.
Hsiang YH; Wu HY; Liu LF
Cancer Res; 1988 Jun; 48(11):3230-5. PubMed ID: 2835157
[TBL] [Abstract][Full Text] [Related]
49. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
Withoff S; Smit EF; Meersma GJ; van den Berg A; Timmer-Bosscha H; Kok K; Postmus PE; Mulder NH; de Vries EG; Buys CH
Lab Invest; 1994 Jul; 71(1):61-6. PubMed ID: 8041119
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase II alpha promoter.
Herzog CE; Zwelling LA
Biochem Biophys Res Commun; 1997 Mar; 232(3):608-12. PubMed ID: 9126321
[TBL] [Abstract][Full Text] [Related]
51. p53 regulates the minimal promoter of the human topoisomerase IIalpha gene.
Sandri MI; Isaacs RJ; Ongkeko WM; Harris AL; Hickson ID; Broggini M; Vikhanskaya F
Nucleic Acids Res; 1996 Nov; 24(22):4464-70. PubMed ID: 8948636
[TBL] [Abstract][Full Text] [Related]
52. Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha.
McPherson JP; Deffie AM; Jones NR; Brown GA; Deuchars KL; Goldenberg GJ
Anticancer Res; 1997; 17(6D):4243-52. PubMed ID: 9494516
[TBL] [Abstract][Full Text] [Related]
53. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226.
Wang H; Jiang Zg; Wong YW; Dalton WS; Futscher BW; Chan VT
Biochem Biophys Res Commun; 1997 Aug; 237(2):217-24. PubMed ID: 9268689
[TBL] [Abstract][Full Text] [Related]
54. Regulation of topoisomerase II alpha and beta in HIV-1 infected and uninfected neuroblastoma and astrocytoma cells: involvement of distinct nordihydroguaretic acid sensitive inflammatory pathways.
Mandraju RK; Kondapi AK
Arch Biochem Biophys; 2007 May; 461(1):40-9. PubMed ID: 17391642
[TBL] [Abstract][Full Text] [Related]
55. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development.
Capranico G; Tinelli S; Austin CA; Fisher ML; Zunino F
Biochim Biophys Acta; 1992 Aug; 1132(1):43-8. PubMed ID: 1380833
[TBL] [Abstract][Full Text] [Related]
56. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer.
Lee CH; Liu M; Sie KL; Lee MS
Anticancer Res; 1996; 16(4A):1805-11. PubMed ID: 8712704
[TBL] [Abstract][Full Text] [Related]
57. Human cytomegalovirus induces expression of cellular topoisomerase II.
Benson JD; Huang ES
J Virol; 1990 Jan; 64(1):9-15. PubMed ID: 2152837
[TBL] [Abstract][Full Text] [Related]
58. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
59. Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine.
Kang MR; Chung IK
Mol Pharmacol; 2002 Apr; 61(4):879-84. PubMed ID: 11901227
[TBL] [Abstract][Full Text] [Related]
60. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
